GASTROINTESTINAL STROMAL TUMORS
Clinical trials for GASTROINTESTINAL STROMAL TUMORS explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMORS trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer drug SGI-110 tested in rare tumors – study halted early
Disease control TerminatedThis study tested the drug SGI-110 in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, or HLRCC kidney cancer that had not responded to other treatments. The goal was to see if the drug could shrink tumors or slow their growth. The …
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
Experimental combo therapy trial halted early
Disease control TerminatedThis early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated, so result…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC